Zydus Cadila to start phase two of clinical trials

NEW DELHI: Drug maker Zydus Cadila will start phase 2 clinical trials to establish the efficacy of its Covid-19 vaccine candidate from Thursday, the company said, adding that “…its plasmid DNA vaccine to prevent COVID-19, ZYCOV-D, was found to be safe and well tolerated in the Phase I clinical trial.”